Jim Cramer Notes Johnson & Johnson is “Really Bearing Down on High-Growth Pharma”

Group 1 - Johnson & Johnson (NYSE: JNJ) is being highlighted as a strong investment opportunity, particularly in the high-growth pharmaceutical sector, with a focus on cancer treatments [1] - The company is divesting from non-proprietary products, such as artificial joints, to concentrate on its core pharmaceutical business [1] - Johnson & Johnson offers a yield of over 2.7%, making it an attractive option for investors looking for stable returns [1] Group 2 - Johnson & Johnson develops and sells a wide range of healthcare products, including pharmaceuticals and medical technologies, with a focus on areas such as immunology, oncology, neuroscience, cardiovascular care, and infectious diseases [2] - The company also provides surgical systems, orthopedic solutions, cardiovascular devices, and vision care products, indicating a diverse product portfolio [2]